May 17, 2023

Imbria Pharmaceuticals to Participate in SVB Securities Biopharma Private Company Connect

BOSTON, Mass., May 17, 2023 – Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced that Anne Prener, M.D., Ph.D., president and chief executive officer, Jai Patel, MRCP(UK), chief medical officer, and Komal Joshi, chief financial officer, will participate in the SVB Securities Biopharma Private Company Connect, taking place virtually on May 24-25, 2023. Investor one-on-one meetings with the Imbria management team may be requested through SVB Securities.